SK49999A3 - Oxadiazole derivatives, process for their preparation and their use as medicaments - Google Patents

Oxadiazole derivatives, process for their preparation and their use as medicaments Download PDF

Info

Publication number
SK49999A3
SK49999A3 SK499-99A SK49999A SK49999A3 SK 49999 A3 SK49999 A3 SK 49999A3 SK 49999 A SK49999 A SK 49999A SK 49999 A3 SK49999 A3 SK 49999A3
Authority
SK
Slovakia
Prior art keywords
formula
phenyl
substituted
radical
alkyl
Prior art date
Application number
SK499-99A
Other languages
English (en)
Slovak (sk)
Inventor
Michael Brenner
Roland Maier
Marion Wienrich
Thomas Weiser
Rainer Palluk
Wolf-Dietrich Bechtel
Angelo Sagrada
Helmut Ensinger
Uwe Pschorn
Raffaele Cesana
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of SK49999A3 publication Critical patent/SK49999A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SK499-99A 1996-10-18 1997-10-15 Oxadiazole derivatives, process for their preparation and their use as medicaments SK49999A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19643037A DE19643037A1 (de) 1996-10-18 1996-10-18 Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
PCT/EP1997/005693 WO1998017652A1 (de) 1996-10-18 1997-10-15 Oxadiazole, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel

Publications (1)

Publication Number Publication Date
SK49999A3 true SK49999A3 (en) 1999-11-08

Family

ID=7809114

Family Applications (1)

Application Number Title Priority Date Filing Date
SK499-99A SK49999A3 (en) 1996-10-18 1997-10-15 Oxadiazole derivatives, process for their preparation and their use as medicaments

Country Status (31)

Country Link
US (1) US6277872B1 (cs)
EP (1) EP0934288B1 (cs)
JP (1) JP3333523B2 (cs)
KR (1) KR20000049253A (cs)
CN (1) CN1086698C (cs)
AR (1) AR008496A1 (cs)
AT (1) ATE315034T1 (cs)
AU (1) AU737552B2 (cs)
BG (1) BG103251A (cs)
BR (1) BR9714354A (cs)
CA (1) CA2268954C (cs)
CO (1) CO4920253A1 (cs)
CZ (1) CZ138099A3 (cs)
DE (2) DE19643037A1 (cs)
EE (1) EE9900147A (cs)
ES (1) ES2256880T3 (cs)
HR (1) HRP970553A2 (cs)
HU (1) HUP0001652A3 (cs)
ID (1) ID18613A (cs)
IL (1) IL129315A0 (cs)
NO (1) NO312512B1 (cs)
NZ (1) NZ335598A (cs)
PE (1) PE11199A1 (cs)
PL (1) PL332432A1 (cs)
RU (1) RU2182905C2 (cs)
SK (1) SK49999A3 (cs)
TR (1) TR199900848T2 (cs)
TW (1) TW413678B (cs)
WO (1) WO1998017652A1 (cs)
YU (1) YU40997A (cs)
ZA (1) ZA979220B (cs)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19816880A1 (de) * 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Neue Diphenyl-substituierte 5-Ring-Heterocyclen, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
IT1300056B1 (it) * 1998-04-17 2000-04-05 Boehringer Ingelheim Italia Eterocicli con anello a 6 termini difenil-sostituiti loro procedimento di preparazione e loro impiego come farmaci
US6107313A (en) * 1998-10-02 2000-08-22 Combichem, Inc. Dopamine receptor antagonists
CA2362385C (en) 1999-02-15 2009-08-11 Eisai Co., Ltd. Heterodiazinon compound
EP1070708B1 (en) * 1999-07-21 2004-01-14 F. Hoffmann-La Roche Ag Triazole derivatives
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
CN1313465C (zh) * 1999-08-19 2007-05-02 Nps药物有限公司 杂多环化合物及其用于制备代谢性谷氨酸受体拮抗剂的应用
EP1582519A3 (en) * 1999-08-19 2005-12-21 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US6579880B2 (en) * 2000-06-06 2003-06-17 Ortho-Mcneil Pharmaceutical, Inc. Isoxazoles and oxadiazoles as anti-inflammatory inhibitors of IL-8
PT1300396E (pt) 2000-06-12 2009-04-20 Eisai R&D Man Co Ltd Compostos de 1,2-di-hidropiridina, processos para a sua preparação e sua utilização
CA2742411A1 (en) * 2000-09-18 2002-03-21 Eisai R&D Management Co., Ltd. Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations
CA2438991C (en) * 2001-02-21 2010-08-17 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
DE60226756D1 (de) * 2001-10-04 2008-07-03 Merck & Co Inc Heteroarylsubstituierte tetrazolmodulatoren des metabotropischen glutamatrezeptors-5
MY151199A (en) 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
AR040847A1 (es) * 2002-08-09 2005-04-20 Astrazeneca Ab 1,2,4-oxadiazoles como moduladores de receptores de glutamato metabotropicos, para el tratamiento de desordenes neurologicos y psiquiatricos
DE10240818A1 (de) * 2002-08-30 2004-05-13 Grünenthal GmbH Substituierte 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazol-Derivate
BR0313755A (pt) 2002-08-23 2005-06-21 Rigel Pharmaceuticals Inc Composto, métodos para inibir a replicação ou proliferação de um vìrion da hepatite c e para tratar ou prevenir uma infecção por hcv, e, composição
GB0303503D0 (en) * 2003-02-14 2003-03-19 Novartis Ag Organic compounds
RU2338746C2 (ru) * 2003-02-27 2008-11-20 НьюроСёрч А/С Новые диазабициклические арильные производные, содержащие их фармацевтические композиции и их применение
US7326790B2 (en) 2003-05-02 2008-02-05 Rigel Pharmaceuticals, Inc. Diphenylisoxazole compounds and hydro isomers thereof
US7115642B2 (en) 2003-05-02 2006-10-03 Rigel Pharmaceuticals, Inc. Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating HCV infection
US7220745B2 (en) 2003-05-15 2007-05-22 Rigel Pharmaceuticals Heterocyclic compounds useful to treat HCV
WO2005049065A2 (en) 2003-11-19 2005-06-02 Rigel Pharmaceuticals, Inc. Synergistic combinations of dihaloacetamide with interferon or ribavirin for treatment hcv infections
BRPI0418149A (pt) 2003-12-24 2007-04-17 Prosidion Ltd derivados heterocìclicos como agonistas do receptor de gprc
US7514434B2 (en) 2004-02-23 2009-04-07 Rigel Pharmaceuticals, Inc. Heterocyclic compounds having an oxadiazole moiety and hydro isomers thereof
MY148809A (en) 2004-07-06 2013-05-31 Eisai R&D Man Co Ltd Crystals of 1,2-dihydropyridine compound and their production process
JPWO2006109876A1 (ja) * 2005-04-08 2008-11-20 エーザイ・アール・アンド・ディー・マネジメント株式会社 不随意運動治療剤
CA2606106A1 (en) 2005-05-02 2007-03-08 Rigel Pharmaceuticals, Inc. Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses
GB0510142D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
HUP0500920A2 (en) * 2005-10-05 2007-07-30 Richter Gedeon Nyrt Oxadiazole derivatives, process for their preparation and their use
DE102005061427A1 (de) * 2005-12-22 2007-06-28 Grünenthal GmbH Substituierte Oxadiazol-Derivate
TWI404706B (zh) * 2006-01-11 2013-08-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
US20110207704A1 (en) * 2006-12-15 2011-08-25 Abbott Laboratories Novel Oxadiazole Compounds
CN101562977A (zh) * 2006-12-15 2009-10-21 艾博特公司 新的二唑化合物
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
KR20100083814A (ko) * 2007-10-04 2010-07-22 메르크 세로노 에스. 에이. 옥사디아졸 디아릴 화합물
WO2009082398A1 (en) * 2007-12-21 2009-07-02 University Of Notre Dame Du Lac Antibacterial compounds and methods of using same
WO2010000372A2 (en) 2008-06-09 2010-01-07 Ludwig-Maximilians-Universität München New drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
RU2398770C1 (ru) * 2009-03-27 2010-09-10 Учреждение Российской академии наук Институт молекулярной генетики РАН (ИМГ РАН) Меченная тритием 3-[5-(2-фторфенил)-1,2,4-оксадиазол-3-ил]бензойная кислота
US9095596B2 (en) 2009-10-15 2015-08-04 Southern Research Institute Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such
JP6219955B2 (ja) * 2012-08-24 2017-10-25 トレヴェンティス コーポレイションＴｒｅｖｅｎｔｉｓ Ｃｏｒｐｏｒａｔｉｏｎ ベンゾフラザン抗アミロイド化合物および方法
RS58976B1 (sr) 2014-02-27 2019-08-30 Treventis Corp Antiamiloidna jedinjenja koja sadrže benzofuran
JP6493394B2 (ja) 2014-04-24 2019-04-03 住友化学株式会社 ジアリール−アゾール化合物
US10662164B2 (en) 2014-09-25 2020-05-26 University Of Notre Dame Du Lac Non-beta lactam antibiotics
CN107286174B (zh) * 2016-04-11 2020-08-18 上海勋和医药科技有限公司 取代2,4-(1h,3h)嘧啶二酮作为parp抑制剂及其应用
WO2018049404A1 (en) 2016-09-12 2018-03-15 University Of Notre Dame Du Lac Compounds for the treatment of clostridium difficile infection
JP7283699B2 (ja) 2017-05-12 2023-05-30 マックス－プランク－ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 黒色腫の治療または予防において使用するためのフェニル－ヘテロ環－フェニル誘導体
US10676467B2 (en) 2017-06-30 2020-06-09 Washington University Compositions for binding sphingosine-1-phosphate receptor 1 (S1P1), imaging of S1P1, and methods of use thereof
CN113226286B (zh) 2018-12-14 2024-08-20 卫材R&D管理有限公司 1,2-二氢吡啶化合物的水基药物制剂
US20240398775A1 (en) 2021-09-15 2024-12-05 University Of The Ryukyus Pharmaceutical composition for use in treating cognitive decline or for use in treating overweight or obesity
JPWO2023042888A1 (cs) 2021-09-15 2023-03-23
EP4173485A1 (en) 2021-10-27 2023-05-03 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Protein aggregation inhibiting compounds for plant disease control

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4003909A (en) * 1974-07-22 1977-01-18 E. R. Squibb & Sons, Inc. [(1,2,4-Oxadiazol-3-yl)phenyl]carbamic or thiocarbamic acid esters
JPS52272A (en) * 1975-10-17 1977-01-05 Takeda Chem Ind Ltd Process for preparing 1,2,4-oxadiazole derivatives
DE2801509A1 (de) * 1978-01-12 1979-07-19 Schering Ag 1,2,4-oxadiazolderivate, verfahren zur herstellung dieser verbindungen sowie diese enthaltende selektive herbizide mittel
JPS58150576A (ja) * 1982-03-03 1983-09-07 Sumitomo Chem Co Ltd 新規な１，２，４−オキサジアゾ−ル誘導体
EP0276432A3 (de) * 1986-12-12 1988-10-26 Ciba-Geigy Ag Schädlingsbekämpfungsmittel
DE3905242A1 (de) * 1989-02-21 1990-08-23 Basf Ag Verfahren zur herstellung von phenyloxdiazolylanilinen
JPH02250873A (ja) * 1989-03-24 1990-10-08 Mitsubishi Petrochem Co Ltd １，２，４―オキサジアゾール誘導体及びそれを有効成分とする除草剤
NZ234760A (en) * 1989-08-18 1991-09-25 Sterling Drug Inc Antiviral oxazole compounds and compositions
DK443489D0 (da) * 1989-09-08 1989-09-08 Ferrosan As Substituerede urinstofforbindelser, deres fremstilling og anvendelse
JPH04295470A (ja) * 1991-03-22 1992-10-20 Wakamoto Pharmaceut Co Ltd モノアミンオキシダーゼ−ｂ酵素阻害活性を有する１，２，４−オキサジアゾール誘導体及びその製造法
US5492919A (en) * 1991-08-03 1996-02-20 Smithkline Beecham P.L.C. 5-HT4 receptor antagonists
WO1994017048A1 (fr) * 1993-01-21 1994-08-04 Nippon Soda Co., Ltd. Derive d'oxadiazole
DE4401107A1 (de) * 1994-01-17 1995-07-20 Bayer Ag 3-Aryl-alkenyl-1,2,4-oxadiazol-Derivate
DE4401108A1 (de) * 1994-01-17 1995-07-20 Bayer Ag 1,2,4-Oxadiazol-Derivate
DE19528189A1 (de) * 1995-08-01 1997-02-06 Basf Ag Benzolderivate mit einem heterocyclischen Rest

Also Published As

Publication number Publication date
WO1998017652A1 (de) 1998-04-30
DE59712543D1 (de) 2006-03-30
JP3333523B2 (ja) 2002-10-15
ZA979220B (en) 1998-04-20
JP2000505089A (ja) 2000-04-25
EP0934288B1 (de) 2006-01-04
NO312512B1 (no) 2002-05-21
ID18613A (id) 1998-04-23
US6277872B1 (en) 2001-08-21
AR008496A1 (es) 2000-01-19
CO4920253A1 (es) 2000-05-29
DE19643037A1 (de) 1998-04-23
CZ138099A3 (cs) 1999-11-17
AU4867697A (en) 1998-05-15
RU2182905C2 (ru) 2002-05-27
HUP0001652A2 (hu) 2001-01-29
CA2268954C (en) 2006-06-13
CN1233245A (zh) 1999-10-27
KR20000049253A (ko) 2000-07-25
EP0934288A1 (de) 1999-08-11
BG103251A (bg) 2000-02-29
HUP0001652A3 (en) 2002-12-28
PE11199A1 (es) 1999-03-03
TR199900848T2 (xx) 1999-06-21
IL129315A0 (en) 2000-02-17
PL332432A1 (en) 1999-09-13
NO991815D0 (no) 1999-04-16
BR9714354A (pt) 2000-04-11
CA2268954A1 (en) 1998-04-30
TW413678B (en) 2000-12-01
HRP970553A2 (en) 1998-08-31
HK1020956A1 (en) 2000-05-26
ATE315034T1 (de) 2006-02-15
ES2256880T3 (es) 2006-07-16
NZ335598A (en) 2001-06-29
NO991815L (no) 1999-04-16
EE9900147A (et) 1999-12-15
YU40997A (sh) 2000-10-30
AU737552B2 (en) 2001-08-23
CN1086698C (zh) 2002-06-26

Similar Documents

Publication Publication Date Title
US6277872B1 (en) Oxadiazoles, processes for their preparation and their use as medicaments
Burbuliene et al. Synthesis and anti-inflammatory activity of derivatives of 5-[(2-disubstitutedamino-6-methyl-pyrimidin-4-yl)-sulfanylmethyl]-3H-1, 3, 4-oxadiazole-2-thiones
EP3981767B1 (en) PHENYLPYRROLIDINONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS
US4716164A (en) As-triazinones
US20080318958A1 (en) New utilities of tricyclic compounds
TWI771303B (zh) 化合物及其於降低尿酸位準之用途(一)
JP2004521908A (ja) Ｍｍｐ阻害剤としてのトリアゾロ化合物
SK168097A3 (en) N-heteroaryl-pyridinesulfonamide derivatives and their use as endothelin antagonists
JP4757382B2 (ja) 神経保護作用を有するトリアゾロン
JPH11513376A (ja) 選択的β▲下３▼−アドレナリン作動剤
JP4589531B2 (ja) 新規ジフェニル置換５員環複素環化合物、それらの製造方法及び薬物としてのそれらの使用
NO840329L (no) Fremgangsmaate for fremstilling av 4-cyanopyridazin-derivater.
EP0089028B1 (de) Neue Theophyllin-Derivate und Verfahren zu ihrer Herstellung
JP3086692B2 (ja) 抗炎症剤としてのフエナメート１，３，４‐チアジアゾール類および１，３，４‐オキサジアゾール類
JP3226920B2 (ja) １，２−ジチオール−３−チオン誘導体に基づく治療組成物
US4925845A (en) 2 heteroaryl 3,3 dialkyl-5-(3 oxo-2,3,4,5 tetrahydro-6 pyridazinyl)-3H-indoles
EP3448853A1 (en) Compounds for modulating aquaporins
NO811667L (no) Fremgangsmaate ved fremstilling av substituerte pyrazinyl-1,2,4-oxadiazoler
JP2001233767A (ja) アポａｉ発現亢進剤
HU197003B (en) Process for producing new isoxazole derivatives and pharmaceuticals comprising same
CN121085942B (zh) 3，5-位取代的咪唑并噻二唑杂环衍生物及其制备方法与应用
JP2002512232A (ja) 新規ジフェニル置換６員環複素環化合物、それらの製造方法及び薬物としてのそれらの使用
USRE33125E (en) 3- and 5-[3-(1-arylureido)]-1,2,4-triazoles
JPH0219111B2 (cs)
CZ303316B6 (cs) 1-Aziridino-1-hydroxyiminomethylové deriváty, zpusob jejich prípravy a léciva obsahující tyto slouceniny